Oncology

With Christoph Korpus at the helm, Byondis signals a strategic shift to accelerate its innovative cancer therapies through new partnerships and commercialization.

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

Satri-cel, the world's first CAR-T therapy for solid tumors, is set to launch in China, offering a powerful new weapon against advanced stomach cancers.

TAE Life Sciences' new therapy combines precision radiation with immunotherapy, showing 100% tumor regression in preclinical studies for hard-to-treat cancers.

Celebrating a decade of challenging norms, AESARA eyes its next chapter in global health, armed with AI, RWE, and a focus on complex diseases.

Blue Faery recognizes two doctors whose groundbreaking research in immunotherapy and targeted drugs has created new standards of care for liver cancer patients.

A new alliance between Daiichi Sankyo and ATLATL aims to leverage a unique 'Super Server' model to fast-track novel therapies from Asia to the world.

Early Phase 3 results show gotistobart dramatically extends survival for lung cancer patients with limited options, heralding a potential new standard of care.

As lung cancer becomes a growing crisis for women, the LCRF gala honors two leaders driving change and rallying support for life-saving research.

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

A novel interferon-based therapy from ABION shows promise in preclinical studies, overcoming resistance to current cancer drugs and activating the immune system.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

A groundbreaking trial testing if a coffee infused with an ancient herb can slow prostate cancer recurrence is nearing completion, offering hope for a new era.

New York Medicaid now funds a vital therapy to prevent chemo-induced hair loss, breaking down financial barriers for low-income cancer patients.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

With a multi-billion dollar track record of IPOs and acquisitions, the veteran CEO's appointment signals Frazier's focus on navigating complex markets.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.

Clinical AI launches MAIA™ on Google Cloud Marketplace, using Gemini AI to solve the patient enrollment crisis that stalls 80% of medical studies.

Preclinical data suggests an investigational drug can shift burn wounds from a state of chronic inflammation toward active regeneration and repair.